7TM Pharma successfully conducts clinical phase I trial with its second generation CB1 receptor antagonist

Thursday, February 04, 2010

7TM Pharma today announced that it has successfully conducted and completed a Phase I clinical trial with the drug candidate TM38837, which was discovered internally at 7TM Pharma and is being developed for treatment of obesity and related metabolic disorders.

The Phase I clinical trial was a first in man single ascending dose study in healthy male subjects with additional cohorts in other populations. The aim of the study was to determine the safety and tolerability of a range of single ascending doses of TM38837 and additionally to describe the pharmacokinetic properties of the compound.

Click here to read 7TM's news release.